Spravato vs intranasal ketamine: Which one’s right for me?

Spravato® and intranasal ketamine are often mentioned in the same breath, but they’re far from interchangeable. Both treatments use ketamine’s rapid‑acting antidepressant properties…yet they differ in how they’re formulated, regulated, administered and ultimately experienced by patients.

For people exploring options after traditional antidepressants haven’t delivered enough relief, understanding these differences isn’t just academic: it shapes access, cost, safety and the kind of clinical support they can expect.

AwakeningsKC is the premier provider of ketamine therapy in the Kansas City area.

What Is Ketamine?

Ketamine is a dissociative anesthetic that’s been used in medicine since the 1970s, originally in surgical settings because it provides anesthesia while maintaining breathing and cardiovascular stability. Dissociative anesthetics make you feel detached from your body and surroundings when you take them.

Over the past two decades, researchers discovered something remarkable: at much lower, subanesthetic doses, ketamine can rapidly relieve symptoms of treatment‑resistant depression, suicidal ideation and certain anxiety disorders. That shift, from operating rooms to mental‑health clinics, has reshaped how clinicians think about fast‑acting antidepressant therapy.

Today, ketamine is available in several forms, including IV ketamine, intranasal ketamine and Spravato (esketamine), each with its own regulatory status, dosing structure and clinical oversight. At AwakeningsKC, we use intranasal forms of ketamine – no needle required.

Understanding ketamine itself is the foundation for understanding why these treatment paths differ so meaningfully.

How Does Ketamine Work?

Ketamine works differently from traditional antidepressants. Instead of targeting serotonin or norepinephrine, it influences the glutamate system, the brain’s primary excitatory neurotransmitter. This leads to increased synaptic connectivity, essentially helping the brain rebuild pathways that depression has worn down.

Patients often describe ketamine sessions as producing a sense of detachment from ordinary thought patterns, which can open space for emotional reset and therapeutic insight.

Common short‑term side effects from ketamine include:

• Transient dissociation or perceptual changes
• Dizziness
• Nausea
• Headache
• Increases in blood pressure
• Sedation or fatigue

These typically peak within 40 to 90 minutes after dosing and resolve the same day. Because attention and balance can be affected, patients do not drive on treatment days.

What Is the Difference Between Esketamine and Ketamine?

Ketamine and Spravato are closely related, but they’re not the same medication. The key difference comes down to something called enantiomers, and you don’t need a chemistry background to understand this.

Think of enantiomers like left and right hands. They look similar and are made of the same parts, but they’re mirror images and not interchangeable. Ketamine has two “handed” versions: an R‑form and an S‑form.

• Spravato uses only the S‑form, called esketamine.
• Most intranasal ketamine used off‑label contains both forms together, which is called racemic ketamine.

These differences also matter when comparing Spravato to IV ketamine. IV ketamine delivers racemic ketamine directly into the bloodstream, allowing precise, weight‑based dosing and very fast onset.

Instead, Spravato uses a nasal spray with FDA‑defined dosing and monitoring requirements. Each option comes with its own evidence, logistics, and insurance considerations.

How Ketamine Nasal Spray Is Taken

Intranasal ketamine is taken in a clinic, and the process is simple, structured and guided by a clinician. Here’s what the experience is like:

Preparation

Before anything happens, a clinician walks you through the session and checks in on how you’re feeling. You’re usually seated in a comfortable chair in a quiet room. Many clinics dim the lights or offer blankets or headphones to help you relax.

Using the Nasal Spray

The ketamine comes in a compounded nasal spray bottle, and the clinician instructs you on how to use it. The spray may have a mild taste or smell, and some people notice a brief cooling or tingling sensation in the nose.

Each spray contains a specific amount of ketamine, and the clinician guides you through how many sprays you’ll take during the session. Because this is off‑label treatment, protocols vary by clinic.

Waiting for Onset

Ketamine absorbs quickly through the nasal passages. Most people begin to feel the effects within minutes. You stay seated or reclined while the clinician monitors you.

Common early sensations include:

• Lightheadedness
• A gentle slowing of thoughts
• A floaty or dreamy feeling

The Experience

As the medication takes effect, people often describe:

• Mild dissociation: Feeling a bit removed from everyday thinking
• Shifts in perception: Colors, sounds, or time may feel different
• Emotional openness: Thoughts feel easier to approach

You remain awake and aware throughout the process.

Coming Back

The effects fade over 45–90 minutes, depending on dose and clinic protocol. People often feel:

• Calm
• Reflective
• Emotionally lighter

A clinician checks in before you leave, and you typically need a ride home because ketamine can temporarily affect coordination and attention.

Spravato vs. Intranasal Ketamine: What Do They Treat?

Spravato and intranasal ketamine both come from the same family of medications, but they’re used for different purposes and within very different clinical frameworks. Understanding what each one treats helps clarify why their protocols, insurance coverage, and oversight look so different.

Spravato: FDA‑Approved Uses

Spravato is approved to treat:

• Treatment‑resistant depression: For adults who haven’t improved enough after trying multiple antidepressants
• Major depressive disorder with acute suicidal ideation or behavior: Spravato can rapidly reduce severe symptoms while other treatments continue

Because of these approvals, Spravato is used in a highly structured setting, paired with an oral antidepressant, and monitored closely during each session.

Intranasal Ketamine: Off‑Label Uses

Intranasal ketamine is not FDA‑approved for depression or any psychiatric condition, but many clinicians use it off‑label based on emerging research and patient response. This means clinics have more flexibility, but also less standardization.

Clinics may use intranasal ketamine for:

• Depression: Including treatment‑resistant cases
• Anxiety disorders: Such as generalized or social anxiety
• PTSD: Some patients report rapid symptom relief
• Bipolar depression: Used with careful monitoring

Because it’s off‑label, dosing, frequency and treatment structure vary from clinic to clinic.

Why This Difference Matters

Spravato and intranasal ketamine may feel similar to take, but they aren’t interchangeable. Their approved uses shape:

• Insurance coverage
• Treatment structure
• Safety monitoring
• Dosing consistency
• Clinical oversight

Spravato is a regulated, FDA‑approved pathway for specific depression‑related conditions. Intranasal ketamine is a flexible, off‑label option used for a broader range of symptoms but typically paid out‑of‑pocket.

Spravato vs. Intranasal Ketamine: How Does Insurance Look at Them?

The insurance landscape is one of the biggest practical differences between Spravato and intranasal ketamine, and it often shapes which option people can realistically access. Here’s a clear, approachable breakdown:

Why Insurance Treats Them Differently

Spravato and intranasal ketamine aren’t covered the same way because they fall into different regulatory categories:

• Spravato (esketamine) is FDA‑approved for specific depression‑related conditions.
• Intranasal ketamine is not FDA‑approved for depression and is used off‑label, which affects how insurers view it.

This single distinction drives most of the coverage differences.

Spravato: Typically Covered, But with Requirements

Spravato is much more likely to be covered by insurance because it has FDA approval and a formal REMS safety program. Coverage varies by plan, but most insurers treat it like any other specialty mental‑health treatment.

• Prior authorization is almost always required.
• Insurers often ask for documentation of treatment‑resistant depression, meaning multiple antidepressant trials.
• Sessions must occur in a REMS‑certified clinic, which is part of the coverage requirement.
• Many plans cover both the medication and the administration/monitoring time, though copays can vary.

Because Spravato is FDA‑approved, patients can often use commercial insurance, Medicare or Medicaid, depending on the state and plan.

Intranasal Ketamine: Usually Self Pay

Intranasal ketamine is almost always out‑of‑pocket because it’s not FDA‑approved for depression. Insurers typically classify it as an off‑label, non‑covered service.

• Clinics set their own pricing for compounded nasal sprays.
• Costs vary widely depending on the clinic and formulation.
• Some clinics provide superbills so patients can try for partial reimbursement, but success rates are low.
• HSA/FSA funds can sometimes be used, depending on the clinic’s documentation.

Coverage is inconsistent because insurers don’t recognize intranasal ketamine as a standardized, regulated treatment for depression.

What This Means for You

Spravato is often the more accessible option for people relying on insurance, while intranasal ketamine tends to be chosen by those who prefer flexibility, faster access, or lower‑structure treatment, even though it’s self pay.

AwakeningsKC will help verify your insurance, doing everything we can to ensure you receive the care you need.

Spravato vs. Intranasal Ketamine: The Bottom Line

Both Spravato and intranasal ketamine are nasal‑spray treatments that can help some adults with treatment‑resistant depression, but they’re used in different ways.

Intranasal ketamine can sometimes provide faster relief because it works on the brain’s glutamate system, which supports neuroplasticity, the brain’s ability to form new, healthier connections. Spravato offers a standardized, FDA‑approved option with set doses, required monitoring, and more consistent insurance coverage for people who qualify.

Off‑label intranasal ketamine is a compounded spray used in supervised clinics. It gives clinicians more flexibility and is supported by growing real‑world experience, but insurance coverage is less predictable.

Both treatments require in‑clinic monitoring, and patients can’t drive afterward. Choosing between them usually comes down to balancing clinical safety, evidence, access, and your personal priorities.

AwakeningsKC: Your Source for Ketamine Therapy

If you’re exploring whether Spravato or intranasal ketamine could be part of your path forward, you don’t have to navigate that decision alone. At AwakeningsKC, our clinicians provide structured, evidence‑informed guidance to help you:

• Understand your options
• What each treatment involves
• Which approach aligns best with your goals, comfort level, and access needs

Whether you’re seeking a fully FDA‑approved pathway like Spravato or a flexible, off‑label option like intranasal ketamine, we’re here to support you with clarity, compassion, and personalized care.

Reach out today to start a conversation about your treatment options and take a meaningful step toward feeling better.

---

Frequently Asked Questions

Is Spravato the same as ketamine?

Spravato contains esketamine, the S‑enantiomer of ketamine, while most intranasal ketamine products are racemic and include both R‑ and S‑enantiomers. Both target NMDA receptors and glutamate pathways but are not identical compounds and have different regulatory pathways.

How quickly will I feel better?

Some people notice improvement within hours to days after the first sessions; others need several treatments to see clear changes. Your clinician will set expectations and track progress using standardized scales.

Can I drive after treatment?

No. Because both options can cause transient dissociation, dizziness and sedation, you should avoid driving or operating machinery until the next day.

How long do benefits last?

Durability varies. Many responders transition to maintenance schedules, gradually spacing sessions based on symptoms and function. Lifestyle strategies and psychotherapy can extend benefits.

What if I have a history of substance use disorder?

A history of substance misuse requires careful assessment. Stability, supports and alternative treatments are considered. Intranasal options are not automatically excluded, but risk‑benefit analysis is crucial.

How do I choose between Spravato and intranasal ketamine?

Consider clinical eligibility, safety profile, evidence base, coverage and cost, scheduling needs, and personal preferences.